Elsevier

Clinical Therapeutics

Volume 28, Issue 8, August 2006, Pages 1199-1207
Clinical Therapeutics

Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: A retrospective data analysis

https://doi.org/10.1016/j.clinthera.2006.08.012Get rights and content

Abstract

Objective:

The aim of this study was to compare treatment adherence and health care costs in African Americans versus all other races (All Others) in patients with type 2 diabetes mellitus starting treatment with pioglitazone.

Methods:

In this retrospective cohort study, the North Carolina Medicaid database was used (query dates: July 1, 2000, to June 30, 2003). Using at least 1 code from the International Classification of Diseases, Ninth Revision, Clinical Modification for type 2 diabetes (250.xx) and 1 National Drug Code for antidiabetic medication, we identified a cohort of male and female patients aged ≥18 years with type 2 diabetes who maintained continuous Medicaid eligibility for the entire 36-month follow-up period. Race was categorized as African American and All Others (white, Asian, Native American, Pacific Islander, other) based on self-reported data collected at the time of Medicaid enrollment. Medication adherence was expressed as medication possession ratio (calculated as the number of days of antidiabetic prescription supply dispensed [eg, a 30-day supply] divided by the number of days between the first and last dispensation). Reimbursements made by Medicaid were used to calculate diabetes-related and total health care costs, which included medical and dental care, including costs for regular checkups, office visits, home health care, inpatient and outpatient care, long-term care facility care, and prescription drugs. To compare the differences in medication adherence and annual total and diabetes-related health care costs between African Americans and All Others, multivariate regression analysis was performed using only data from the year after (year 2) the year in which pioglitazone treatment was started (year 1).

Results:

Among the 1073 patients treated with pioglitazone (26.1% men; mean [SD] age, 49.5 [10.6] years; 50.2% African American; mean [SD] total health care costs in year 1, US $7906 [$12,256]; year 2, $9546 [$14,861]), African Americans had significantly higher adherence (62%) to pioglitazone treatment compared with All Others (57%) (P < 0.05) on unadjusted analysis. However, no significant differences in rates of adherence to the medication were found between African Americans and All Others on multivariate regression analysis. African American race was not found to be an independent predictor of increased or decreased annual total health care costs in this population. Significant reductions in total health care costs (2% for every 10% increase in adherence; P < 0.001) and diabetes-related costs (4% for every 10% increase in adherence; P < 0.01) with increased adherence were found.

Conclusions:

On multivariate analysis, this study found no significant differences in treatment adherence between African Americans versus all other races in this population of diabetic patients enrolled in a Medicaid program (query dates: July 1, 2000, to June 30, 2003). A higher adherence rate was associated with significantly lower diabetes-related and total health care costs in this population.

References (42)

  • WagnerE.H. et al.

    Effect of improved glycemic control on health care costs and utilization

    JAMA

    (2001)
  • O'ConnorP.J. et al.

    Care of adults with type 2 diabetes mellitus. A review of the evidence

    J Farn Pract.

    (1998)
  • StrattonI.M. et al.

    Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study

    BMJ

    (2000)
  • TurnerR.C. et al.

    Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)

    JAMA

    (1999)
  • RendersC.M. et al.

    Interventions to improve the management of diabetes in primary care, outpatient, and community settings: A systematic review

    Diabetes Care

    (2001)
  • SmedleyB.D. et al.

    Unequal treatment confronting racial and ethnic disparities in healthcare

    (2002)
  • SaaddineJ.B. et al.

    A diabetes report card for the United States: Quality of care in the 1990s

    Ann Intern Med.

    (2002)
  • HarrisM.I. et al.

    Racial and ethnic differences in glycemic control of adults with type 2 diabetes

    Diabetes Care

    (1999)
  • Hill-BriggsF. et al.

    Medication adherence and diabetes control in urban African Americans with type 2 diabetes

    Health Psychol.

    (2005)
  • SchectmanJ.M. et al.

    The association between diabetes metabolic control and drug adherence in an indigent population

    Diabetes Care

    (2002)
  • BalkrishnanR. et al.

    Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: A retrospective data analysis

    Curr Med Res Opin.

    (2004)
  • Cited by (37)

    • Pharmacological treatment of type 2 diabetes in Saudi Arabia: A consensus statement from the Saudi Society of Endocrinology and Metabolism (SSEM)

      2021, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
      Citation Excerpt :

      Adherence to religion and culture is widely cherished and respected in Saudi Arabia. Adherence to medications is generally poor among people with T2D and this has been linked to lower attainment of treatment targets for hemoglobin A1C (HbA1C), blood pressure, and low-density lipoprotein (LDL) cholesterol, and consequently higher healthcare costs and poorer clinical outcome [5–12]. Although, the importance of patient’s adherence to medications is recognized in the general guidelines documents, it is however, not prioritized or listed as a deciding factor in the choice of glucose-lowering agents recommended in any of the current treatment algorithms of T2D.

    • Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure

      2017, Health Policy
      Citation Excerpt :

      The impact of a $5 increase in copayment on the percentage of patients being adherent was examined in three studies (p < 0.05) (two in DM [46,51] and one in HF [49]) and all studies concluded in a statistically significant (p < 0.05) decrease of adherent patients. Among the 29 studies examined the relationship between medication adherence and resource utilization, health and/or economic outcomes, 22 [44,50,59–78] had been conducted in DM populations, six [53–58] in patients with HF, while both patients with DM or HF were included in one study [79]. Ten [44,59,60,63,64,70,71,73,75,76] out of twelve studies evaluating the impact of medication adherence change on health outcomes among patients with DM demonstrated a statistically significant (p < 0.05) association.

    • Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population

      2014, Research in Social and Administrative Pharmacy
      Citation Excerpt :

      Previous research reports mixed findings regarding the effects that age, gender, and race have in compliance with drug therapy across varying chronic conditions. Age, gender, and race have been significant predictors in logistic regression models,18,21 with males having better adherence levels than females,18 White patients having better adherence levels than Black patients,18,22,43–46 and older patients having better adherence levels than younger patients.11 In the current study, no significant effects were seen on either persistence or adherence due to age, but the effects due to gender and race were the same as other studies.

    View all citing articles on Scopus
    View full text